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Abstract: Although the relationship between protein-bound uremic toxins (PBUTs) and cardiac
structure and cardiac mortality in chronic kidney disease (CKD) has been studied in the past,
the association between cardiac dysfunction and PBUTs has not yet been studied. We therefore
evaluated the association between impaired peak cardiac performance and the serum free and total
concentrations of potentially cardiotoxic PBUTs. In a cross-sectional study of 56 male CKD patients
(stages 2–5 (pre-dialysis)) who were asymptomatic with no known cardiac diseases or diabetes we
measured peak cardiac power (CPOmax), aerobic exercise capacity (VO2max), and echocardiographic
parameters of cardiac morphology and evaluated their association with PBUTs. The serum total
and free concentrations of indoxyl sulfate (IXS), p-cresyl sulfate (PCS), p-cresyl glucuronide, indole
acetic acid, and hippuric acid showed significant negative correlation with CPOmax and VO2max.
IXS and PCS were independently associated with CPOmax and VO2max even after controlling for
eGFR. No correlation between left ventricular mass index (LVMI) and PBUTs was seen. The present
study for the first time has demonstrated the association between subclinical cardiac dysfunction in
CKD and serum levels of a panel of PBUTs. Further studies are required to evaluate the mechanism
of cardiotoxicity of the individual uremic toxins.
Keywords: uremic toxins; cardiac function; cardiac power; aerobic exercise capacity
Key Contribution: The study demonstrates for the first time the association between protein-bound
uremic toxins and subclinical cardiac dysfunction, the precursor of symptomatic heart failure,
in patients with chronic kidney disease.
1. Introduction
Cardiovascular disease (CVD) is the predominant cause of mortality and morbidity in chronic
kidney disease (CKD) and end-stage renal disease (ESRD). Several pathophysiological mechanisms are
being studied to understand the mechanism of CVD in CKD. Among the potentially putative agents
of CVD in CKD, there is a growing interest in the role of protein-bound uremic toxins (PBUTs) [1,2].
PBUTs such as indoxyl sulfate (IXS) and p-cresyl sulfate (PCS) have been shown to elicit a wide
Toxins 2018, 10, 520; doi:10.3390/toxins10120520 www.mdpi.com/journal/toxins
Toxins 2018, 10, 520 2 of 13
range of toxicity such as endothelial dysfunction, vascular calcification, and induction of oxidative
stress [3–7]. More importantly, clinical studies have shown that some of the PBUTs are associated with
cardiovascular and all-cause mortality [5,8]. However, the association between cardiac dysfunction
and PBUTs has not yet been studied.
In our recently published paper we demonstrated the presence of asymptomatic cardiac
dysfunction in CKD patients (stages 2–5 (pre-dialysis)) with no pre-existing cardiac disease or diabetes
mellitus [9]. The study also evaluated the association between asymptomatic cardiac dysfunction in
CKD and the conventional renal biochemical parameters such as serum creatinine, urea, inorganic
phosphate, calcium, and bicarbonate. In the present study, we evaluated the association between
such subclinical cardiac dysfunction and the serum levels of a panel of potentially cardiotoxic PBUTs.
In addition, we also evaluated the association between PBUTs and cardiac dimensions and aerobic
exercise capacity.
2. Results
2.1. Patient Characteristics
There were 56 male CKD patients with a mean age of 46.8 ± 12.5 years covering the spectrum of
CKD from stages 2 to 5 (pre-dialysis). The mean eGFR was 38.5 ± 24.1 mL/min/1.73 m2. The patient
characteristics such as anthropometry, biochemistry, and parameters of central haemodynamics and
exercise capacity across the CKD stages are presented in Table 1. The etiologies of CKD were as
follows (number of patients in brackets): IgA nephropathy (16), polycystic kidney disease (12), reflux
nephropathy and chronic pyelonephritis (13), membranoproliferative glomerulonephritis (3), Alport’s
nephropathy (2), hypertensive nephropathy (1), focal segmental glomerulosclerosis (2), minimal
change disease (1), and uncertain etiology (6). None of the study participants had any history of
ischaemic, arrhythmic, or valvular heart diseases or diabetes mellitus. Patients were asymptomatic
from a cardiac point of view (all NYHA class I). No patient had angina or ECG evidence of cardiac
ischaemia or arrhythmia during cardiopulmonary exercise testing (CPX). Of the 56 patients, 62.5%
were receiving angiotensin-converting enzyme inhibitors (ACE-I), 34.5% angiotensin receptor blockers,
19.6% β-blockers, and 25% statins.
Table 1. Patient characteristics.
Patient Characteristics CKD 2(n = 14)
CKD 3
(n = 15)
CKD 4
(n = 16)
CKD 5
(n = 11)
ANOVA
(p)
Age (years) 38.1 ± 8.8 52.2 ± 9.1 48.6 ± 12.7 47.9 ± 15.4 0.01 *
BMI (kg/m2) 26.6 ± 3.6 28.6 ± 4.1 26.6 ± 4.2 29.5 ± 4.1 0.16
Biochemistry
eGFR (mL/min) 73.5 ± 7.9 43.2 ± 7.9 21.5 ± 4.3 11.9 ± 2.4 <10−3 *
Creatinine (µmoL/L) 104.6 ± 10.9 158.1 ± 2.6 294.8 ± 56.7 550.1 ±227.4 <10
−3 *
Urea (mmoL/L) 7.3 ± 1.8 11.5 ± 2.4 20.1 ± 3.6 27.0 ± 8.7 <10−3 *
Calcium (mmoL/L) 2.4 ± 0.1 2.4 ± 0.1 2.3 ± 0.1 2.3 ± 0.2 0.54
Phosphate (mmoL/L) 1.1 ± 0.2 1.1 ± 0.1 1.2 ± 0.1 1.6 ± 0.7 0.001 *
Bicarbonate (mmoL/L) 28 ± 2.5 25.9 ± 2.5 22.9 ± 3.3 21.0 ± 3.5 <10−3 *
Uric acid (mg/dL) 8.6 ± 2.0 10.9 ± 2.3 9.7 ± 2.2 10.4 ± 2.2 0.05
PTH (pmoL/L) 6.1 ± 4.8 16.9 ± 25.7 25.4 ± 17.4 47.6 ± 38.9 0.005 *
Haemoglobin (g/dL) 15.1 ± 1.2 14 ± 1.4 13.2 ± 1.6 12.1 ± 1.3 <10−3 *
CPX parameters
Peak Qt (L/min) 22.1 ± 2.1 20.1 ± 2.1 19.1 ± 2.2 19.1 ± 1.9 0.001 *
Peak MAP (mmHg) 106.4 ± 8.9 107.6 ± 7.9 104.2 ± 10.0 101.0 ± 8.9 0.32
Peak HR (beats/min) 169.7 ± 18.1 151.8 ± 12.8 149.3 ± 23.7 145.1 ± 18.5 0.007 *
CPOmax (W) 5.23 ± 0.76 4.79 ± 0.61 4.44 ± 0.55 4.29 ± 0.63 0.002 *
VO2max (L/min) 3.13 ± 0.57 2.70 ± 0.47 2.61 ± 0.63 2.43 ± 0.30 0.009 *
Peak C(a-v)O2 (dL/min) 14.2 ± 2.1 13.4 ± 2.0 13.5 ± 2.04 12.8 ± 1.7 0.40
BMI: body mass index, Qt: cardiac output, MAP: mean arterial pressure, HR: heart rate, CPOmax: peak cardiac
power, VO2max: peak O2 consumption, C(a-v)O2: arteriovenous difference in O2 concentration.* p < 0.05 on ANOVA
across chronic kidney disease (CKD) stages.
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The free and total concentrations of the PBUTs such as Indoxyl sulfate (IXS), p-cresyl
sulfate (PCS), p-cresyl glucuronide (PCG), indole acetic acid (IAA), hippuric acid (HA),
and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF) of the full CKD cohort are presented
in Table 2. Figures 1 and 2 show the total and free concentrations of the PBUTs across CKD stages.
Since CMPF is bound to protein for nearly 100%, only total concentrations are reported. The difference
in the free concentrations of all PBUTs across the CKD stages was significant on ANOVA (all p < 0.05).
On multiple comparisons, for all PBUTs, the free concentration in CKD 5 was significantly higher
compared to those in CKD 2 and 3. For IXS and PCG, the free concentration in CKD 5 was significantly
higher compared to those in CKD stages 2, 3, and 4.
Table 2. Total and free concentrations of the assayed protein-bound uremic toxins (PBUTs).
Uremic Toxins
Serum Concentration
Median (25th pct, 75th pct)
(n = 56)
IXS (mg/dL) Total 0.222 (0.101, 0.598)
Free 0.006 (0.002, 0.015)
PCS (mg/dL) Total 0.782 (0.303, 1.418)
Free 0.017 (0.007, 0.031)
PCG (mg/dL) Total 0.013 (0.004, 0.035)
Free 0.011 (0.002, 0.029)
IAA (mg/dL) Total 0.057 (0.040, 0.101)
Free 0.005 (0.003, 0.011)
HA (mg/dL) Total 0.255 (0.119, 0.379)
Free 0.084 (0.038, 0.137)
CMPF (mg/dL) Total 0.071 (0.035, 0.156)
Indoxyl sulfate (IXS), p-cresyl sulfate (PCS), p-cresyl glucuronide (PCG), indole acetic acid (IAA), hippuric acid
(HA), and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF).
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Figure 1. Serum total concentration of PBUTs across CKD stages. CKD 2 (n = 14), CKD 3 (n = 15), CKD 4
(n = 16), and CKD 5 (n = 11). Outliers: ◦ >1.5 × interquartile range (IQR) and * >3.0 × IQR. Indoxyl
sulfate (IXS), p-cresyl sulfate (PCS), p-cresyl glucuronide (PCG), indole acetic acid (IAA), Hippuric
acid (HA), and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF).
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Figure 2. Serum free concentration of PBUTs across CKD stages. CKD 2 (n = 14), CKD 3 (n = 15), CKD 4
(n = 16), and CKD 5 (n = 11). Outliers: ◦ >1.5 × IQR and * >3.0 × IQR. Indoxyl sulfate (IXS), p-cresyl
sulfate (PCS), p-cresyl glucuronide (PCG), indole acetic acid (IAA), and Hippuric acid (HA).
2.2. Association between PBUTs and Peak Cardiac Performance
2.2.1. Peak Cardiac Power Output (CPOmax)
The total and free concentrations of IXS, PCS, PCG, IAA, and HA showed significant negative
correlation with CPOmax. No significant correlation existed between CMPF and CPOmax. (Tables 3
and 4).
Table 3. Correlation coefficients (r) between serum total concentration of PBUTs and parameters of
cardiac function, structure, and exercise capacity.
Study Param ters IXS PCS PCG IAA CMPF HA
CPOm x −0.44 ** −0.58 ** −0.52 ** −0.33 * −0.35 **
1-7 Peak Qt −0.41 ** −0.48 ** −0.45 ** −0.27 * −0.42 **
1-7 Peak MAP −0.35 ** −0.30 *
1-7 Peak HR −0.41 ** −0.27 * −0.30 *
1-7 VO2max −0.36 ** −0.53 ** −0.43 ** −0.37 ** −0.30 *
1-7 Peak C(a-v)O2 −0.36 ** −0.26 * −0.31 *
1-7 LVMI
1-7 IVSd 0.30 *
Heat map showing negative correlations in
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Table 4. Correlation coefficients (r) between serum free concentration of PBUTs and parameters of
cardiac function, structure, and exercise capacity.
Study Parameters IXS PCS PCG IAA HA
CPOmax −0.48 ** −0.51 ** −0.52 ** −0.40 ** −0.29 *
1-6 Peak Qt −0.41 ** −0.44 ** −0.45 ** −0.33 * −0.40 **
1-6 Peak MAP −0.29 * −0.29 *
1-6 Peak HR −0.41 ** −0.31 *
1-6 VO2max −0.41 ** −0.48 ** −0.42 ** −0.41 ** −0.38 **
1-6 Peak C(a-v)O2 −0.332 * −0.31 *
1-6 LVMI
1-6 IVSd 0.33 * 0.32 *
Heat map showing negative correlations in
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MAP: mean arterial pressure; peak HR: peak heart rate; VO2max: aerobic exercise capacity; C(a-v)O2: arteriovenous
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sulfate (IXS), p-cresyl sulfate (PCS), p-cresyl glucuronide (PCG), indole acetic acid (IAA), and hippuric acid (HA).
2.2.2. Peak Cardiac Output (Peak Qt)
The total and free concentrations of IXS, PCS, PCG, IAA, and HA showed significant negative
correlation with peak Qt, the volume generating capacity of the heart. No correlation was seen with
CMPF (Tables 3 and 4).
2.2.3. Peak Mean Arterial Pressure (Peak MAP)
The total and free concentrations of PCS and PCG showed significant negative correlation with
peak MA , the pressure generating capacity of the heart. No correlation was seen between IXS, IAA,
HA, or CMPF and peak MAP (Tables 3 and 4).
2.2.4. Peak Heart Rate (Peak HR)
The total concentrations of PCG, IAA, and HA and the free concentrations of PCG and IAA
showed significant negative correlation with the peak HR. The other toxins did not show any significant
correlations with peak HR (Tables 3 and 4).
2.3. Association between PBUTs and Aerobic Exercise Capacity
2.3.1. Aerobic Exercise Capacity (VO2max)
The total and free concentrations of IXS, PCS, PCG, IAA, and HA showed significant negative
correlation with VO2max. No significant correlation existed between CMPF and VO2max (Tables 3
and 4).
2.3.2. Arteriovenous O2 Difference [C(a-v)O2]
The total concentrations of PCS, PCG, and IAA and free concentrations of PCS and IAA showed
significant negative correlation with C(a-v)O2 (Tables 3 and 4).
2.4. Independent Association of PBUTs with CPOmax and VO2max
In partial least squares (PLS) multiple regression analysis, serum free concentrations of IXS and
PCS were independently associated with percentage predicted CPOmax for age even after controlling
for eGFR. The standardised coefficients (β) were −0.35 for IXS and −0.38 for PCS. An independent
association was also demonstrated between free IXS and free PCS concentration and percentage of
predicted VO2max for age even after controlling for eGFR. The standardised coefficients (β) were −0.34
for IXS and −0.30 for PCS. Furthermore, an independent association was demonstrated between free
PCS and C(a-v)O2 (β = −0.26). For these associations, all p are <0.05. The associations of IXS and PCS
Toxins 2018, 10, 520 6 of 13
with CPOmax and VO2max are shown in Figures 3 and 4. Figure 5 shows the association between PCS
and C(a-v)O2.
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2.5. Association between Non-Protein-Bound Uremic Toxin and Peak Cardiac Performance and Aerobic
Exercise Capacity
No correlation was seen between uric acid, a representative small molecule, and the above
measures of cardiac performance or the measures of aerobic exercise capacity in the study cohort.
2.6. Association between PBUTs and Cardiac Dimensions
Left ventricular hypertrophy (LVH) (LVMI > 116 g/m2) was present in 14.6% of the patients,
and LV concentric remodelling was present in 37.5% of the patients. No association between PBUTs
and cardiac dimensions such as left ventricular mass, left ventricular mass index, relative wall
thickness, left ventricular diameter in systole or diastole, or left atrial diameter was seen. However,
interventricular septal thickness showed a positive correlation with the serum free concentrations of
IXS (r = 0.33, p = 0.02) and PCS (r = 0.32, p = 0.03) (Table 4). The cardiac peak power-to-mass ratio
expressed as peak CPO (in watts) per 100 g of left ventricular mass showed a significant negative
correlation with the serum free concentrations of IXS (r = −0.29, p = 0.04), PCS (r = −0.29, p = 0.04),
and PCG (r = −0.34, p = 0.02).
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2.7. Effect of Beta Blockers
Of the 11 patients who were on beta blockers, 10 of them were in CKD stages 4 or 5. Therefore,
linear regression was performed, controlling for eGFR, to compare haemodynamic parameters between
CKD patients who were on beta blockers and those who were not. The results showed that there
were no significant differences in CPOmax (∆ −0.04 W, p = 0.87) or peak CO (∆ 0.38 L/min, p = 0.63).
The mean peak HR was lower in the beta blocker group by 28.15 beats/min (p < 10−3), whereas the
mean peak SV was greater in the beta blocker group by 30.65 mL (p < 10−3), offsetting the reduction in
peak HR.
3. Discussion
This study demonstrated for the first time the association between protein-bound uremic toxins
and subclinical cardiac dysfunction in CKD. Of the 30 or more protein-bound uremic toxins that have
previously been reported [1], we tested the leading candidates that might be cardiotoxic, and we
found that both free IXS and free PCS were independently and significantly associated with subclinical
cardiac dysfunction in CKD.
The present study is the first instance where the association between subclinical cardiac
dysfunction, the precursor of symptomatic heart failure, and PBUTs has been shown. Although
previous studies demonstrated an association between IXS and the incidence of HF in CKD [10],
no association was demonstrable between IXS levels and markers of cardiac dysfunction such as LV
ejection fraction or serum B-type natriuretic peptides (BNP) [11]. This is probably because the studies
relied on resting measures or surrogate markers of cardiac dysfunction.
The resting performance of a failing myocardium is kept as normal as possible by compensatory
mechanisms; hence, measurements of the resting performance of the heart are poorly discriminatory
between healthy and diseased states [12]. In our study we therefore measured the peak performance of
the heart, which exposed the subclinical cardiac dysfunction in CKD and demonstrated its relationship
with PBUTs. In addition, the study also demonstrated an association between individual uremic toxins
and haemodynamic characteristics such as peak cardiac output (peak Qt), peak mean arterial pressure
(peak MAP), and peak heart rate (peak HR), which are markers of volume generating capacity, pressure
generating capacity, and chronotropic reserve of the heart, respectively.
The study has also demonstrated for the first time the independent association between PBUTs
and aerobic exercise capacity. Fick’s equation states that aerobic exercise capacity is a product of cardiac
output and arteriovenous O2 difference [VO2 = Qt ×C(a− v)O2]. The study showed that the PBUTs
were not only associated with impaired cardiac function but also with impaired arteriovenous O2
difference, which is a measure of peripheral O2 extraction by exercising skeletal muscles. IXS has been
shown to accumulate in skeletal muscles in experimental uremia and induce metabolic alterations [13].
This could be a potential mechanism of skeletal myopathy related to PBUTs.
In the present study, in asymptomatic CKD patients, in the absence of co-morbid cardiac disease or
diabetes, only 14.6% of the subjects had LVH; in addition, the study did not demonstrate any association
between LVMI and PBUTs. However, there was association between PBUTs and early changes of
cardiac hypertrophy such as interventricular septal thickness. More importantly, there was association
between PBUTs and the LV power-to-mass ratio, a marker of cardiac pathological remodelling.
In the present study, beta blockade therapy was not shown to influence cardiac power.
The reduction in peak HR associated with beta blockade was offset by the increase in SV; hence,
there was no net effect on cardiac performance. Almost all CKD patients were treated with RAAS
blockade, but if this has affected the results, the effect was uniform.
Mechanistic insights into the cardiotoxicity of PBUTs have been gained predominantly through
the investigation of biochemical pathways using cultured cardiomyocytes or fibroblasts in the presence
of PBUTs [14]. IXS and PCS have been the most studied. Studies testing other toxins and in vivo
studies are rare. Nevertheless, these studies offer some significant insights into the cardiotoxicity
of PBUTs. IXS was shown to induce cardiomyocyte hypertrophy through activation of the NFkB
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pathway and induce fibrosis through inhibition of the AMPK pathway [15,16]. Furthermore, molecular
signatures of pathological remodelling, such as increased expression of mRNA for beta MHC and
ANP, were seen in IXS-induced cardiotoxicity [17]. In addition, increased expression of TGF beta and
IL-6, which are potent mediators of cardiac fibrosis, has also been shown [17]. Induction of oxidative
stress by PBUTs is also a recurrent finding. The mechanism is implicated in the profibrotic effect of IXS
and the pro-apoptotic effect of PCS [18,19].
It is pertinent to note that these pathways involved in the cardiotoxicity of PBUTs have striking
similarities to the pathways seen in the pathological remodelling of the heart that leads to heart
failure [20]. Several decades of heart failure research have shown that the consequences of such
pathological remodelling are impaired cardiomyocyte energetics, altered expression and function of
contractile proteins, impaired excitation–contraction coupling, etc., leading to impaired cardiomyocyte
function and eventually myocardial dysfunction [21].
Although the current literature demonstrates the role of PBUTs in inducing cardiac ultrastructural
changes such as fibrosis and hypertrophy, studies on the effects of these toxins on the cardiomyocyte
function are still lacking. We believe that the relationship shown in the present study between
individual PBUTs and cardiac dysfunction and the biomechanical characteristics of such dysfunction
would help in the selection of candidate toxins for further in vitro and in vivo studies wherein the
effects of PBUTs on cardiomyocyte physiology could be evaluated. Thus, the present work could lead
to several “reverse translational” studies to further the knowledge on the cardiotoxicity of uremic
toxins. Ultimately, these may reveal novel therapeutic targets.
4. Limitations
The cross-sectional nature of the study only allows for the demonstration of an association between
uremic toxins and cardiac dysfunction. Further longitudinal studies of uremic-toxin-reducing strategies
are required to demonstrate a causal relationship between uremic toxins and cardiac dysfunction.
5. Conclusions
This study demonstrated the association between PBUTs and early subclinical cardiac dysfunction
in CKD. Although the effect of PBUTs on cardiac structure and ultrastructure has been well studied in
the past, the present study for the first time has highlighted the role of PBUTs in cardiac dysfunction.
We believe that the study results will open new avenues of research in exploring the mechanisms of
myocardial dysfunction induced by protein-bound uremic toxins.
6. Materials and Methods
6.1. Study Subjects
Asymptomatic male CKD patients (stages 2 to 5 (pre-dialysis), n = 56) were recruited from
the renal outpatient clinic of a tertiary U.K. referral center for cardiopulmonary exercise testing
(CPX). The inclusion criteria were age of >18 years, male gender, and CKD stage 2 to 5 (pre-dialysis).
The exclusion criteria were diabetes mellitus; any known cardiac diseases (ischaemic, arrhythmic,
or valvular); limitation of exercise ability due to significant musculoskeletal, cardiovascular, pulmonary,
hepatic, neurological, or other nonrenal medical disorders; and clinical hypervolemia. The present
study is limited to the male gender alone to minimise confounders that arise because of gender and
body composition on central haemodynamics [22–24]. Venous blood samples were taken prior to
CPX to assay uremic toxins. Routine renal biochemistry tests were also performed. The estimated
glomerular filtration rate (eGFR) was calculated using the 4-variable modification of diet in the renal
disease Modification of Diet in Renal Disease (MDRD) formula [25]. The study was approved by the
South Yorkshire Research Ethics Committee [Ref: 11/H1310/8, Date: 1 November 2011]. All subjects
provided informed written consent before participation. These clinical investigations conformed with
the Declaration of Helsinki.
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6.2. Assessment of Peak Cardiac Performance
A specialised cardiopulmonary exercise test (CPX) was employed to measure peak cardiac
power (CPOmax) and cardiac haemodynamics noninvasively using the CO2 rebreathing method.
Full methodological details have been described in previous reports [9,26,27]. A summary of the
methodology is presented here.
Cardiopulmonary Exercise Test
Resting measures: The subjects had resting measurements taken for O2 consumption and CO2
production, respiratory rate, and cardiac output using a Medgraphics CardiO2 Analytic System
(Medgraphics Corp., St. Paul, MN, USA). Resting cardiac output was calculated using the Collier CO2
rebreathing method [28,29].
Determination of aerobic capacity (VO2max): Subjects then underwent an incremental exercise test
on a treadmill according to a standard Bruce protocol, and every 3 min, the speed and incline of the
treadmill were increased according to the protocol until the subjects reached volitional exhaustion.
Throughout the treadmill test, O2 consumption, CO2 production, end-tidal partial pressure of CO2,
tidal ventilation, and respiratory rate were measured using breath-to-breath analysis. The ventilatory
(“anaerobic”) threshold was measured by the V-slope method [30]. A 12-lead ECG was monitored
throughout, and the subject’s heart rate (HR) was obtained from this. Blood pressure (BP) was
measured at rest and at 3 min intervals up to, and including, maximal exercise by auscultation
and sphygmomanometry.
Determination of cardiac output: After resting at least 40 min, a second treadmill test was
performed. The speed and incline of the treadmill were adjusted manually. The subjects exercised on
the treadmill to 95% of their VO2 max as established in the incremental exercise test. Two or three cardiac
output measurements were made using the Defare’s CO2 rebreathing method [31]. The blood pressure
was measured using a sphygmomanometer after each determination of cardiac output. Peak cardiac
power output is calculated using the formula CPO = (Qt ×MAP)× K where Qt is the cardiac output,
MAP is the mean arterial pressure, and K (2.22 × 10−3) is a conversion factor to convert CPO into
the SI unit of power, Watt. MAP is calculated using the formula MAP = DBP+ 0.412 (SBP− DBP)
where SBP and DBP are systolic and diastolic blood pressures, respectively. VO2 is calculated using
Fick’s equation, VO2 = Qt × C(a− v)O2, where C(a-v)O2 is the arteriovenous O2 difference which is
a measure of peripheral O2 extraction by the exercising skeletal muscles. Simultaneous measurement
of Qt and VO2 in the present study enabled the estimation of C(a-v)O2 using the above equation.
6.3. Echocardiogram
A 2-dimensional study was performed in the standard parasternal long-axis and short-axis planes
followed by apical 4-chamber, apical 5-chamber, and apical 2-chamber planes to evaluate the cardiac
structure and left ventricular contractility. The left ventricular ejection fraction (LVEF) was calculated
by Simpson’s biplane method [32] and the left ventricular mass index (LVMI) was calculated by the
Devereaux method [33]. The echocardiographic parameters were also utilised to measure the left
ventricular power-to-mass ratio, a marker of pathological remodelling, by expressing peak cardiac
power per 100 g of left ventricular mass (W/100 g of LV mass) [34].
6.4. Protein-Bound Uremic Toxin Assays
Blood samples were obtained from study subjects prior to CPX exercise testing. After clotting for
30 min the samples were centrifuged (10 min), and the serum stored as 0.5 mL aliquots in a −80 ◦C
freezer. Indoxyl sulfate (IXS), p-cresyl sulfate (PCS), p-cresyl glucuronide (PCG), indole acetic acid
(IAA), hippuric acid (HA), and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF) were
analysed by high-performance liquid chromatography (HPLC) at the nephrology department of the
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Ghent University Hospital, Ghent, Belgium as described in the previously published methodological
papers [35,36].
For quantification of the total fraction, serum samples were deproteinised by heat (95 ◦C, 30 min).
After cooling (10 min on ice), samples were filtered through a Centrifree-filter (cut-off: 30 kDa; Millipore,
Billerica, MA, USA). To determine the free fraction, untreated serum samples were ultrafiltered prior
to heating. Indoxyl sulfate (λex: 272 nm, λem: 374 nm), p-cresyl sulfate and p-cresyl glucuronide
(λex: 264 nm, λem: 290 nm), and indole-3-acetic acid (λex: 272 nm, λem: 340 nm) were detected using
a Waters 2475 fluorescence detector, while uric acid, hippuric acid and CMPF were detected using a
Waters 996 photodiode array detector at 300 nm, 245 nm, and 254 nm respectively (Waters Alliance
2695 device (Waters, Zellik, Belgium) connected to a Waters fluorescence detector and a UV detector).
6.5. Statistical Analysis
CPOmax was the primary outcome measure. The association between CPOmax and serum total
and free concentrations of PBUTs was evaluated using Pearson’s correlation. Logarithmic transformed
values of PBUT concentration were used for analysis. Similar associations with other haemodynamic
parameters such as peak cardiac output (Qt), peak mean arterial pressure (MAP) and peak heart
rate (HR), and aerobic exercise capacity (VO2max) and peripheral O2 extraction (C(a-v)O2) were also
assessed. Furthermore, the correlation between PBUTs and measures of cardiac dimension and LV
power-to-mass ratio was also assessed.
The independent association between PBUTs and CPOmax, controlling for eGFR, was assessed
using partial least squares multiple regression analysis (PLS), as the use of a standard multiple
regression analysis was precluded by collinearity between the independent variables. Absolute
values of PBUT concentration (rather than log-transformed values) were used for such analysis.
Free concentrations of PBUTs were used for analysis as only the free unbound fractions of the toxins
are biologically active and, hence, clinically relevant. As CPOmax is influenced by age, percentage
predicted CPOmax for age, as calculated using a previously published regression equation [22], was
used as the dependent variable. Thus, in the PLS analysis, percentage predicted CPOmax was the
dependent variable, and IXS, PCS, PCG, IAA, HA, and eGFR were the independent variables. Similar
analyses were performed with percentage predicted VO2max as the dependent variable. Data are
presented as mean± SD or median (25th pct, 75th pct) as appropriate. p < 0.05 is considered significant.
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